ABSTRACT
Glutamate neurotransmission has been considered as one of pathogenetic factors of schizophrenia though all antipsychotics widely used in modern psychiatric practice are dopamine antagonists. LY2140023 is a selective agonist for metabotropic glutamate 2/3 (mGlu2/3) receptors with antipsychotic effect. In the present study, we have assessed clinical efficacy of LY2140023 in patients with schizophrenia compared to the control group receiving olanzapine in a randomized double-blind placebo-controlled trial. The statistically significant reduction of positive and negative symptoms measured with the PANSS (p<0.001) was observed for both antipsychotics at week 4 of treatment compared to placebo. The treatment with LY2140023 was safe and well-tolerated; treated patients did not differ from the placebo group by hyperprolactinemia and extrapyramidal symptoms, and weight gain. The results suggest that the agonist for 2/3 (mGlu2/3) receptors has antipsychotic properties and provides a new, alternative to dopamine agonists, method for pharmacotherapy of schizophrenia.
Subject(s)
Amino Acids/therapeutic use , Antipsychotic Agents/therapeutic use , Receptors, Metabotropic Glutamate/agonists , Schizophrenia/drug therapy , Adolescent , Adult , Aged , Amino Acids/adverse effects , Antipsychotic Agents/adverse effects , Female , Humans , Male , Middle Aged , Treatment Outcome , Young AdultABSTRACT
One hundred and forty two patients with ICD-10 diagnosis of depression from 7 research scientific were treated with tianeptine (coaxil); 124 have completed the treatment course. Moderate depression was diagnosed in 111 patients (89.5%) and severe depression--in 13 (10.5%). A duration of the last episode before treatment was 7.1 +/- 1.7 months. The mean score by Hamilton depression scale was 24.4 +/- 4.0. The patients received tianeptine as a monotherapy in dosage 12.5 mg, 3 times daily during 6 weeks (65-year olds and older were given 25 mg daily). Tianeptine proved to be an antidepressant with balanced action, i.e., exerted thymoanaleptic, anxiolytic and activating effects. The treatment was beneficial for 70.4% of the patients; remission was revealed in 58%. The medication was well tolerated with rare and weakly pronounced side effects.
Subject(s)
Antidepressive Agents, Tricyclic/therapeutic use , Depression/drug therapy , Thiazepines/therapeutic use , Adult , Aged , Antidepressive Agents, Tricyclic/adverse effects , Drug Tolerance , Female , Headache/chemically induced , Humans , Male , Middle Aged , Remission Induction , Thiazepines/adverse effectsSubject(s)
Depression/drug therapy , Hypericum/therapeutic use , Phytotherapy , Plants, Medicinal , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Treatment OutcomeSubject(s)
Benzodiazepines , Depressive Disorder/drug therapy , Diazepam , Adolescent , Adult , Aged , Anti-Anxiety Agents/therapeutic use , Benzodiazepinones/therapeutic use , Bipolar Disorder/drug therapy , Female , Humans , Middle Aged , Psychotic Disorders/drug therapy , Schizophrenia/drug therapyABSTRACT
Fenazepam, a potent anxiolytic tranquillizer (7-brom-5/o-chlorphenyl/1,2-dihydro-3H-1,4-benzodiazepin-2-on) was used in the treatment of 173 psychotic patients ( schizophrenia, endogenous depressions, involutional and organic psychoses). In all cases the clinical picture was characterized by anxiety. In 37% of the patients the psychopathological symptomatology disappeared altogether, in 27% there was a significant improvement. The best results were attained in the treatment of anxious-depressive, depersonalization and affective-delusional states. Anxious-depressive conditions in endogenous depressions gave worse results during fenazepam treatment, than in schizophrenia and organic brain disorders. Affective-delusional attacks were arrested by fenazepam in the initial phases. A good effect was also seen in depersonalization.
